Dofetilide Safety and Efficacy Considerations

Patient Selection and Initiation

• The American College of Cardiology recommends calculating creatinine clearance before administering the first dose of dofetilide, as renal function directly determines dosing and risk of toxicity 1
• The European Heart Journal suggests measuring baseline QTc interval—if >500 ms (or >550 ms with ventricular conduction abnormalities), dofetilide is contraindicated 2
• Severe renal dysfunction (CrCl <20 mL/min) is a contraindication for dofetilide, according to the European Heart Journal and the American College of Cardiology 1, 2

Dose Adjustment and Monitoring

• The American College of Cardiology recommends adjusting the initial dose of dofetilide according to creatinine clearance: CrCl 40-60 mL/min: 250 mcg twice daily 1
• The American College of Cardiology suggests measuring QTc 2-3 hours after each dose for the first 5 doses, and reducing the dose by 50% if QTc increases >15% from baseline OR exceeds 500 ms (550 ms with ventricular conduction abnormalities) 2
• If QTc exceeds 500 ms after the second dose, the American College of Cardiology recommends discontinuing dofetilide permanently 2

Special Populations

• The European Heart Journal notes that dofetilide and amiodarone are the only antiarrhythmics proven safe in heart failure, making dofetilide a reasonable choice when sinus rhythm maintenance is the goal 3, 4, 5
• The Journal of the American College of Cardiology reports that in the DIAMOND CHF trial, dofetilide reduced AF incidence (1.9% vs 6.6% placebo) and hospital readmissions for heart failure without increasing mortality 3, 5
• The European Heart Journal states that dofetilide may be considered as a second-line agent in stable CAD patients, though more experience is needed before recommending it as first-line therapy 3

Safety and Efficacy

• The Journal of the American College of Cardiology reports that the risk of TdP varies significantly by patient population and dosing protocol, with a risk of 3.3% in heart failure patients (DIAMOND CHF) 4
• The European Heart Journal notes that 76% of TdP episodes occur within the first 3 days of therapy, justifying the mandatory inpatient monitoring period 3, 5
• The American College of Cardiology suggests that dofetilide has no effect on heart rate or blood pressure, unlike beta-blockers, calcium channel blockers, or amiodarone 4
• The Journal of the American College of Cardiology reports that dofetilide is one of only two antiarrhythmics (along with amiodarone) proven safe in patients with ejection fraction ≤35% 4, 6, 7

Contraindications and Precautions for Dofetilide in Atrial Fibrillation Treatment

Medication Interactions and Patient Conditions

• The American Heart Association recommends that hypokalemia or hypomagnesemia must be corrected before initiating dofetilide, as potassium-depleting diuretics increase the risk of torsades de pointes 8
• The European Society of Cardiology suggests that while dofetilide can be used in heart failure patients, careful monitoring is required due to increased risk of torsades de pointes, with a benefit that must be weighed against risk, though the DIAMOND-MI trial showed potential benefit in selected post-MI patients 9, 10
• The American College of Cardiology advises that dofetilide should never be initiated outside of a hospital setting, to minimize the risk of torsades de pointes 11